CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Vitro Biopharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Vitro Biopharma Inc
3200 CHERRY CREEK DRIVE SOUTH, SUITE 410
Phone: (720) 859-4120p:720 859-4120 DENVER, CO  80209  United States Ticker: VODG VODG
Business Summary
Vitro Biopharma, Inc. is a biotechnology company targeting autoimmune diseases and inflammatory disorders, with an ancillary focus in the research services and cosmeceutical fields. The Company is focused on developing therapeutic products, its stem cell technology, patent portfolio and proprietary technology and cell lines for applications in autoimmune disorders and inflammatory disease processes and stem cell research. The Company is engaged in the development of cellular therapeutic candidates intended to address significant unmet medical needs. In the United States, the Company is authorized to conduct two clinical trials under two Food and Drug Administration (FDA) Investigational New Drug applications to assess the safety and efficacy of AlloRx Stem Cell therapy in PTHS and Long COVID. It is also engaged in various other activities, including providing research services and stem cell products, as well as cosmeceuticals, through its wholly owned subsidiary, namely InfiniVive MD.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
1/31/202410/31/2023YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board JohnPacks 67 1/19/2023 1/19/2023
Chief Executive Officer, Director ChristopherFurman 53 7/6/2022 7/6/2022
Chief Financial Officer NathanHaas 25 10/1/2021
3 additional Officers and Directors records available in full report.

Business Names
Business Name
Fitore Inc.
Fitore Nutrition
Infinivive MD
6 additional Business Names available in full report.

General Information
Number of Employees: 10 (As of 10/31/2023)
Outstanding Shares: 5,245,620 (As of 1/31/2024)
Shareholders: 3,200
Stock Exchange: ASE
Federal Tax Id: 841012042
Fax Number: (720) 859-4110


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 18, 2024